Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY GroupLJUIF 86 Net Margin % is 9.27% as of Dec. 2025, which is 52% below its 10-year median of 19.39. GuruFocus rates LJUIF with a GF Score™ of 86/100 and a GF Value™ of $0.51. The stock has 8 warning signs investors should review. Among 961 Drug Manufacturers companies, SSY Group ranks better than 68.05% on this metric.
Net margin is calculated as Net Income divided by its Revenue. SSY Group's Net Income for the
six
months ended in Dec. 2025 was $24.1 Mil. SSY Group's Revenue for the
six
months ended in Dec. 2025 was $259.4 Mil. Therefore, SSY Group's net margin for the quarter that ended in Dec. 2025 was 9.27%.
The historical rank and industry rank for SSY Group's Net Margin % or its related term are showing as below:
LJUIF'
s Net Margin % Range Over the Past 10 Years
Min: 11.3 Med: 19.39 Max: 24.51
Current: 11.3
LJUIF's Net Margin % is ranked better than 68.05% of 961
companies
in the Drug Manufacturers industry
Industry Median: 5.54
vs LJUIF: 11.30
SSY Group (OTCPK:LJUIF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
SSY Group Net Margin % Related Terms
SSY Group Net Margin % Historical Data
* Premium members only.
The historical data trend for SSY Group's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where SSY Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (LJUIF) has a Net Margin % of 9.27% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on SSY Group and its competitors. This is 52% below median its historical median of 19.39. Over the past decade, SSY Group's Net Margin % has ranged from 11.30 to 24.51. According to the industry distribution chart, SSY Group ranks #307 out of 961 companies in the Drug Manufacturers industry, placing it in the top 31.9%.
Is SSY Group's Net Margin % too high?
SSY Group's current Net Margin % of 9.27% is 52% below median its 10-year median of 19.39. Over the past 10 years, this metric has ranged from a low of 11.30 to a high of 24.51. The Drug Manufacturers industry median Net Margin % is 5.54. SSY Group's value of 9.27% is 67.3% above this industry median. Based on the distribution chart, SSY Group ranks #307 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, SSY Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does SSY Group's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SSY Group ranks #307 out of 961 companies for Net Margin %. This puts SSY Group in the upper half of its industry. The industry median Net Margin % is 5.54. SSY Group's value of 9.27% is 67.3% above this benchmark. Historically, SSY Group's own Net Margin % has ranged from 11.30 to 24.51 over the past decade. While the company's 10-year median is 19.39 vs. the industry median of 5.54, SSY Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.54, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SSY Group's current Net Margin % of 9.27% is 67.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on SSY Group and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current Net Margin % is 9.27%, which is 52% below median its own 10-year median of 19.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
SSY Group (LJUIF) has a current Net Margin % of 9.27%. The stock's GF Value™ is $0.51, compared to a current price of $0.40 — trading 21.1% below its estimated fair value. The current Net Margin % is 9.27%, which is 52% below median its 10-year median of 19.39 and 67.3% above the Drug Manufacturers industry median of 5.54. SSY Group's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For SSY Group (LJUIF), the current Net Margin % is 9.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (LJUIF) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of $0.40 is trading 21.1% below its estimated GF Value™ of $0.51.
Key valuation signals for LJUIF:
Net Margin %: 9.27% (52% below median its 10-year median of 19.39)
GF Value™: $0.51 vs. price of $0.40 (21.1% below fair value)
Industry Position: 67.3% above the Drug Manufacturers median (#307 of 961)
No single metric tells the full story. See the LJUIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
86GF Score
Get the complete analysis for LJUIF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LJUIF has been successfully added to your 
